Related Experiment Video
Updated: Jan 9, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Decoding Immune Influence: A Mendelian Randomisation Study on Dilated Cardiomyopathy
Wei Gao1,2,3,4,5, Hui Wang1,2,3,4,5, Jian-Long Wang1,2,3,4,5
1Heart Center, Tianjin Third Central Hospital Tianjin, China.
Insights
Elevated CD4+ regulatory T-cells (Tregs) causally increase the risk of dilated cardiomyopathy (DCM). This immune cell trait highlights the role of immune dysregulation in DCM development, impacting cardiovascular health.
Area of Science:
- Immunology
- Cardiovascular Disease Genetics
- Genetic Epidemiology
Background:
- Dilated cardiomyopathy (DCM) is a major cause of heart failure, influenced by genetic and environmental factors.
- The immune system's role in DCM pathogenesis is not fully understood.
- Investigating immune cell traits offers potential insights into DCM development.
Purpose of the Study:
- To investigate the causal relationship between immune cell traits and DCM risk using Mendelian randomization (MR).
- To identify specific immune factors that may contribute to the development of DCM.
Main Methods:
- A two-sample MR analysis was performed using genome-wide association study data for 731 immune cell traits and DCM.
- Inverse-variance weighting was the primary analysis method, with MR-Egger and MR-PRESSO used for sensitivity analyses.
- Genetic mapping and pathway enrichment analyses were conducted on identified immune traits.
Main Results:
- An increased relative count of CD4+ regulatory T-cells (Tregs) was causally associated with a higher risk of DCM.
- Each unit increase in genetically predicted CD4+ Tregs increased DCM odds by 14.4% (OR 1.144, p=9.36E-05).
- Genetic mapping linked this immune trait to genes involved in inflammation and leukocyte adhesion in cardiovascular tissues.
Conclusions:
- Elevated CD4+ Treg levels are implicated as a causal factor in DCM development.
- Immune dysregulation, specifically involving Tregs, plays a critical role in DCM pathogenesis.
- Further research is needed to confirm these findings and explore underlying biological mechanisms.
Background:
Dilated cardiomyopathy (DCM) is a significant contributor to heart failure, originating from complex interactions between genetic and environmental factors. Although the immune system has been implicated in various cardiovascular diseases, its precise role in DCM pathogenesis remains ambiguous. This study uses Mendelian randomisation (MR) to explore the causal relationship between diverse immune cell traits and DCM risk.
Methods:
We conducted a two-sample MR analysis using summary-level data from genome-wide association studies of 731 immune cell traits and DCM. Our primary method employed fixed- and random-effects inverse-variance weighting, complemented by sensitivity analyses - such as MR-Egger, Mendelian Randomisation-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) - to address potential pleiotropy. Additionally, genetic mapping and pathway enrichment analyses were performed on the key immune trait associated with DCM risk.
Results:
Our analysis revealed that an increased relative count of CD4+ regulatory T-cells (Tregs) is causally associated with a higher risk of DCM. Specifically, each unit increase in the genetically predicted proportion of CD4+ Tregs corresponded to a 14.4% increase in the odds of developing DCM (OR 1.144; 95% CI [1.069-1.223], p=9.36E-05, false discovery rate (FDR) = 0.0684). No reverse causal effects were observed. Genetic mapping further indicated an association between this immune trait and several genes enriched in cardiovascular tissues, with involvement in inflammatory responses and leukocyte adhesion.
Conclusion:
These findings provide novel evidence supporting a causal role of elevated CD4+ Treg levels in DCM development and highlight the critical impact of immune regulation in its pathogenesis. Future studies are warranted to validate these associations and elucidate the underlying biological mechanisms.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

